PCSK9 and Hypercholesterolemia: LDL-C: Low-Density Lipoprotein Cholesterol; FOURIER: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; ODYSSEY LONG TERM: Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy; ODYSSEY COMBO II: Efficacy and Safety of Alirocumab Vs.